News & AnalysisKyverna Therapeutics rallies $85m Series BKyverna Therapeutics, a cell therapy company, has secured $85 million in Series B financing.ByIris Dorbian26 January 2022•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs